Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002195
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service

Brief Summary:
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Amprenavir Drug: Lamivudine Drug: Zidovudine Phase 3

Detailed Description:
This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of retrovir and epivir.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 290 participants
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection.

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients must have:

  • HIV-positive status.
  • Screening viral load >= 10,000 copies/mm3 14 days prior to entry.
  • CD4+ cell counts >= 200 cells/mm3 14 days prior to entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Clinical diagnosis of AIDS (CDC 1993 Classification C).

Concurrent Medication:


Terfenadine, astemizole, cisapride, triazolam, medazolam, and ergotamine/dihydroergotamine-containing regimens.

Patients with the following prior conditions are excluded:

Clinically relevant hepatitis in the previous 6 months.

Prior Medication:


  • Greater than 4 weeks of any nucleoside antiretroviral therapy.
  • Previous therapy with an HIV protease inhibitor.
  • Cytotoxic chemotherapeutic agents within 4 weeks prior to entry.
  • Immunomodulating agents within 3 months prior to entry.

Prior Treatment:


Radiotherapy within 4 weeks prior to entry.

Risk Behavior:


Current alcohol or illicit drug use that may interfere with the patient's ability to comply with the dosing schedule or protocol evaluations.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002195

Layout table for location information
United States, California
Pacific Oaks Research
Beverly Hills, California, United States, 90211
United States, District of Columbia
Dr Bruce Rashbaum
Washington, District of Columbia, United States, 20037
United States, Florida
Community Research Initiative of South Florida
Coral Gables, Florida, United States, 33146
Community Research Initiative of Central Florida
Maitland, Florida, United States, 32751
Univ of Miami School of Medicine
Miami, Florida, United States, 33136
United States, Illinois
Chicago Ctr for Clinical Research
Chicago, Illinois, United States, 60610
United States, Massachusetts
Community Research Initiative of New England
Brookline, Massachusetts, United States, 02445
United States, New York
Saint Vincent's AIDS Ctr
New York, New York, United States, 10011
United States, Tennessee
Methodist Hosp
Memphis, Tennessee, United States, 38104
Sponsors and Collaborators
Glaxo Wellcome
Layout table for additonal information Identifier: NCT00002195    
Other Study ID Numbers: 264D
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: November 1998
Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Therapy, Combination
HIV Protease Inhibitors
VX 478
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Acquired Immunodeficiency Syndrome
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
HIV Protease Inhibitors